7 min read
Common Peptide Myths & Misconceptions
Separating frequently repeated claims from what the published research actually shows.
Myth: "Research use only" labels are just a legal workaround
This misunderstands the regulatory framework. Research peptides genuinely are not licensed medicines — they have not gone through Phase I/II/III clinical trials, have no established human safety data, and are not approved by the MHRA or any equivalent authority for human use. The research-only designation is accurate. Selling them as medicines for human use without MHRA licensing would constitute a criminal offence under Human Medicines Regulations 2012. The label reflects legal reality, not a loophole.
Myth: Higher purity means higher potency
Purity and potency are not the same variable. Purity refers to what percentage of the vial's mass is the target compound (e.g., 99.4% BPC-157 means 99.4% of the mass is pure BPC-157). Potency refers to biological activity — which depends on correct sequence, correct folding, and intact disulfide bonds. A 99% pure peptide with incorrect sequence is not potent. A 95% pure peptide with correct sequence may be highly active in research models. This is why identity confirmation (mass spectrometry) is as important as purity (HPLC).
Myth: Oral peptides work the same as injectable research peptides
Most peptides are rapidly degraded by proteolytic enzymes in the gastrointestinal tract and do not survive to reach systemic circulation in biologically meaningful concentrations. This is why research peptides are almost universally reconstituted for subcutaneous or intramuscular administration in animal model research. Some peptides (BPC-157 is a notable exception due to its acid resistance) have been studied orally in animal models, but bioavailability by the oral route is generally very low for most peptide compounds.
Myth: All peptides from any source are equivalent
Peptide quality varies enormously between suppliers. Key variables: (1) sequence accuracy — incorrect amino acid substitutions are common in lower-quality synthesis; (2) purity — impurities can include residual synthesis reagents, truncated sequences, and aggregated forms; (3) sterility — bacterial contamination or endotoxin presence is a critical variable for injectable research; (4) storage and shipping — peptides degraded by poor cold-chain management may appear the same in a vial but be biologically inert. HPLC purity reports and mass spectrometry identity confirmation are the only reliable quality verification methods.
Myth: Peptide research results directly translate to human outcomes
The vast majority of published peptide research is in animal models — primarily rodents. Animal model results do not automatically translate to human outcomes. The history of pharmaceutical research is filled with compounds that showed remarkable effects in rodent models but failed in human trials. BPC-157, TB-500, Epithalon, and most other research peptides have extensive animal model data but very limited or zero published human clinical trials. This is precisely why they remain classified as research compounds rather than approved medicines.
Research Disclaimer: All content on this page is provided for educational and informational purposes only and relates strictly to published preclinical research. Silver Peptide products are supplied for in vitro laboratory research use only. They are not approved by the MHRA, FDA, or any regulatory body for human consumption, injection, or veterinary use. They are not medicines and must not be used as such. Nothing on this page constitutes medical advice.